文献速递骨显像与常规 SPECT肿瘤 PET/CT

乳腺癌骨转移诊断:2-[18F]FDG-PET/CT、18F-NaF-PET/CT、MRI、增强CT与骨显像诊断试验准确性研究的系统综述与网络Meta分析

Diagnosing Bone Metastases in Breast Cancer: A Systematic Review and Network Meta-Analysis on Diagnostic Test Accuracy Studies of 2-[18F]FDG-PET/CT, 18F-NaF-PET/CT, MRI, Contrast-Enhanced CT, and Bone Scintigraphy.
PubMed 文献 · Semin Nucl Med · 2024-11-14

该系统综述与网络Meta分析比较2-[18F]FDG-PET/CT、18F-NaF-PET/CT、MRI、增强CT和骨显像在乳腺癌骨转移诊断中的准确性。纳入40项研究(29项进入Meta分析),2-[18F]FDG-PET/CT、MRI和18F-NaF-PET/CT的敏感性高于增强CT和骨显像;网络Meta分析支持2-[18F]FDG-PET/CT与MRI诊断效能相当。

要点

  • 2-[18F]FDG-PET/CT与MRI诊断乳腺癌骨转移准确性高且相当
  • 2-[18F]FDG-PET/CT、MRI和18F-NaF-PET/CT敏感性优于增强CT和骨显像
  • 作者认为需基于共识阈值开展未来多模态研究进一步探索

核心结论

  • 2-[18F]FDG-PET/CT和MRI对乳腺癌患者骨转移诊断具有高且相当的准确性,二者在敏感性方面均优于增强CT和骨显像。

研究设计与样本

  • 遵循PRISMA-DTA指南的系统综述与网络Meta分析,检索MEDLINE/PubMed、Scopus和Embase截至2024年2月。
  • 纳入高危原发性乳腺癌(III或IV期)或已知原发性乳腺癌怀疑复发(分期或再分期)患者中评估上述五种影像方法诊断骨转移的原始研究。
  • 共纳入40项研究,其中29项进入Meta分析;13项研究仅探讨单一模态。
  • 采用双变量随机效应模型进行Meta分析,并对各模态间敏感性和特异性差异进行网络Meta分析。
  • 偏倚风险采用QUADAS-2评估,筛选、偏倚评估和数据提取由两名研究者独立完成,分歧由第三名研究者解决。

主要发现

  • 2-[18F]FDG-PET/CT的敏感性为0.94(95%CI:0.89-0.97),特异性为0.98(95%CI:0.96-0.99)。
  • MRI的敏感性为0.94(95%CI:0.82-0.98),特异性为0.93(95%CI:0.87-0.96)。
  • 18F-NaF-PET/CT的敏感性为0.95(95%CI:0.85-0.98),特异性为1(95%CI:0.93-1)。
  • 增强CT的敏感性为0.70(95%CI:0.62-0.77),特异性为0.98(95%CI:0.97-0.99);骨显像的敏感性为0.83(95%CI:0.75-0.88),特异性为0.96(95%CI:0.87-0.99)。
  • 多模态研究的网络Meta分析显示2-[18F]FDG-PET/CT与MRI诊断骨转移的估计敏感性差异为0.01(95%CI:-0.16-0.18),特异性差异为-0.02(95%CI:-0.15-0.12)。

关键数值与推荐

  • 2-[18F]FDG-PET/CT:敏感性0.94(95%CI:0.89-0.97),特异性0.98(95%CI:0.96-0.99)。
  • MRI:敏感性0.94(95%CI:0.82-0.98),特异性0.93(95%CI:0.87-0.96)。
  • 18F-NaF-PET/CT:敏感性0.95(95%CI:0.85-0.98),特异性1(95%CI:0.93-1)。
  • 增强CT:敏感性0.70(95%CI:0.62-0.77),特异性0.98(95%CI:0.97-0.99);骨显像:敏感性0.83(95%CI:0.75-0.88),特异性0.96(95%CI:0.87-0.99)。
  • 网络Meta分析中2-[18F]FDG-PET/CT与MRI的敏感性差异0.01(95%CI:-0.16-0.18),特异性差异-0.02(95%CI:-0.15-0.12)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 双变量随机效应模型与网络Meta分析结果在所有模态中一致,但18F-NaF-PET/CT除外。
  • 作者认为需基于共识阈值开展未来多模态研究以进一步探索,尤其是18F-NaF-PET/CT在乳腺癌骨转移诊断中的潜在作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This systematic review and network meta-analysis aimed to compare the diagnostic accuracy of 2-[18F]FDG-PET/CT, 18F-NaF-PET/CT, MRI, contrast-enhanced CT, and bone scintigraphy for diagnosing bone metastases in patients with breast cancer. Following PRISMA-DTA guidelines, we reviewed studies assessing 2-[18F]FDG-PET/CT, 18F-NaF-PET/CT, MRI, contrast-enhanced CT, and bone scintigraphy for diagnosing bone metastases in high-stage primary breast cancer (stage III or IV) or known primary breast cancer with suspicion of recurrence (staging or re-staging). A comprehensive search of MEDLINE/PubMed, Scopus, and Embase was conducted until February 2024. Inclusion criteria were original studies using these imaging methods, excluding those focused on AI/machine learning, primary breast cancer without metastases, mixed cancer types, preclinical studies, and lesion-based accuracy. Preference was given to studies using biopsy or follow-up as the reference standard. Risk of bias was assessed using QUADAS-2. Screening, bias assessment, and data extraction were independently performed by two researchers, with discrepancies resolved by a third. We applied bivariate random-effects models in meta-analysis and network meta-analyzed differences in sensitivity and specificity between the modalities. Forty studies were included, with 29 contributing to the meta-analyses. Of these, 13 studies investigated one single modality only. Both 2-[18F]FDG-PET/CT (sensitivity: 0.94, 95% CI: 0.89-0.97; specificity: 0.98, 95% CI: 0.96-0.99), MRI (0.94, 0.82-0.98; 0.93, 0.87-0.96), and 18F-NaF-PET/CT (0.95, 0.85-0.98; 1, 0.93-1) outperformed the less sensitive modalities CE-CT (0.70, 0.62-0.77; 0.98, 0.97-0.99) and bone scintigraphy (0.83, 0.75-0.88; 0.96, 0.87-0.99). The network meta-analysis of multi-modality studies supports the comparable performance of 2-[18F]FDG-PET/CT and MRI in diagnosing bone metastases (estimated differences in sensitivity and specificity, respectively: 0.01, -0.16 - 0.18; -0.02, -0.15 - 0.12). The results from bivariate random effects modelling and network meta-analysis were consistent for all modalities apart from 18F-NaF-PET/CT. We concluded that 2-[18F]FDG-PET/CT and MRI have high and comparable accuracy for diagnosing bone metastases in breast cancer patients. Both outperformed CE-CT and bone scintigraphy regarding sensitivity. Future multimodality studies based on consented thresholds are warranted for further exploration, especially in terms of the potential role of 18F-NaF-PET/CT in bone metastasis diagnosis in breast cancer.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gerke O, Naghavi-Behzad M, Nygaard ST, et al. Diagnosing Bone Metastases in Breast Cancer: A Systematic Review and Network Meta-Analysis on Diagnostic Test Accuracy Studies of 2-[18F]FDG-PET/CT, 18F-NaF-PET/CT, MRI, Contrast-Enhanced CT, and Bone Scintigraphy. Semin Nucl Med. 2024. PMID: 39547916. doi:10.1053/j.semnuclmed.2024.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。